Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis

Hyunjung Lee, Eun Suk Jung, Jin Ha Lee, Sung Pil Hong, Tae Il Kim, Won Ho Kim, JaeHee Cheon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.

Original languageEnglish
Pages (from-to)1415-1420
Number of pages6
JournalHepato-Gastroenterology
Volume59
Issue number117
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

Mesalamine
Sulfasalazine
Ulcerative Colitis
Recurrence
Therapeutics
Colitis
Anemia
Hemoglobins
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Lee, Hyunjung ; Jung, Eun Suk ; Lee, Jin Ha ; Hong, Sung Pil ; Kim, Tae Il ; Kim, Won Ho ; Cheon, JaeHee. / Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. In: Hepato-Gastroenterology. 2012 ; Vol. 59, No. 117. pp. 1415-1420.
@article{f28c88e212cc4b32b3e3b19db9ea44a8,
title = "Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis",
abstract = "Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6{\%}) had a disease relapse. The cumulative relapse rate was 21.5{\%} after 1 year, 36.5{\%} after 2 years, 46.9{\%} after 3 years and 59.8{\%} after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95{\%} CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95{\%} CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.",
author = "Hyunjung Lee and Jung, {Eun Suk} and Lee, {Jin Ha} and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho} and JaeHee Cheon",
year = "2012",
month = "7",
day = "1",
doi = "10.5754/hge10680",
language = "English",
volume = "59",
pages = "1415--1420",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "117",

}

Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. / Lee, Hyunjung; Jung, Eun Suk; Lee, Jin Ha; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, JaeHee.

In: Hepato-Gastroenterology, Vol. 59, No. 117, 01.07.2012, p. 1415-1420.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis

AU - Lee, Hyunjung

AU - Jung, Eun Suk

AU - Lee, Jin Ha

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Cheon, JaeHee

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.

AB - Background/Aims: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treatment alone have not been well established in the treatment of mild to moderate ulcerative colitis (UC). We evaluated the clinical course of Korean UC patients treated with 5-ASA/sulfasalazine as a maintenance therapy in terms of relapse and predictive factors of clinical relapse. Methodology: A total 256 UC patients, treated with 5-ASA/sulfasalazine at the Severance Hospital between January 2000 and December 2008, were analyzed retrospectively. We sought to investigate relapse rates and to determine independent predictors for relapse. Results: Of the 256 patients, 127 patients (49.6%) had a disease relapse. The cumulative relapse rate was 21.5% after 1 year, 36.5% after 2 years, 46.9% after 3 years and 59.8% after 5 years. On multivariate analysis, left-sided or extensive colitis at diagnosis (hazard ratio=1.46; 95% CI=1.01-2.10; p=0.04) and initial hemoglobin level <10.5g/dL (hazard ratio=0.43; 95% CI=0.22-0.81; p=0.01) were found to be independent factors for clinical relapse. Conclusions: Our study showed that both disease extent at diagnosis and anemia were major predictive factors for clinical relapse after 5-ASA/sulfasalazine therapy for Korean patients with mild to moderate UC.

UR - http://www.scopus.com/inward/record.url?scp=84865185595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865185595&partnerID=8YFLogxK

U2 - 10.5754/hge10680

DO - 10.5754/hge10680

M3 - Article

VL - 59

SP - 1415

EP - 1420

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 117

ER -